

To the OMX Nordic Exchange Copenhagen  
and the press

Release no. 5/2008

### Major shareholder announcement

On February 5, 2008, Pharmexa received information from H. Lundbeck A/S that H. Lundbeck A/S has increased their holdings of Pharmexa shares from 40,000 to 4,974,061 shares, corresponding to 8.33% of the shares in Pharmexa A/S.

Hørsholm, February 5, 2008

Jakob Schmidt  
Chief Executive Officer

### Additional information:

Jakob Schmidt, Chief Executive Officer, tel +45 4516 2525  
Claude Mikkelsen, Vice President, Corporate Affairs and Communication, tel +45 4516 2525  
or +45 4060 2558

**For the editors:** Pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer and serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer, arthritis, bone degeneration and Alzheimer's disease, as well as infectious diseases such as HIV, influenza, hepatitis and malaria. Company programs include GV1001, a peptide vaccine that has entered Phase III trials in pancreatic cancer and Phase II trials in liver cancer, and a number of HIV and hepatitis vaccines in Phase I/II. Collaborative agreements include H. Lundbeck, Innogenetics, IDM Pharma and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 105 employees and is listed on the OMX Nordic Stock Exchange Copenhagen under the trading symbol PHARMX.